Amplia has today released updated data from its ongoing Phase 2a ACCENT trial in pancreatic cancer patients.
The ACCENT trial is investigating narmafotinib in combination with standard-of-care chemotherapy of gemcitabine and Abraxane® in the treatment of advanced pancreatic cancer. This latest data analysis was conducted up to 6 December 2024 and expands on the previous interim data release1 which covered data up to 27 September 2024.
Nine (9) patients have now recorded a confirmed Partial Response. The median duration on trial is now 172 days which is a substantial improvement over historical data for standard-of-care alone. Narmafotinib continues to be generally well-tolerated by patients.
Recruitment for the final cohort of 24 patients is ahead of schedule, with 12 new patients enrolled on the trial since reopening recruitment in October.
Amplia CEO and MD, Dr Chris Burns, commented:
“Adding narmafotinib to the standard-of-care treatment continues to show promise in comparison to the historical data for standard-of-care alone. We’ve recruited over 75% of the trial at this time, and with ongoing positive support from clinicians involved in the study, we are well on track to fully recruit the trial by end of Q1 2025. In addition, we have been reassured by our clinical team in Korea that the recent political situation in the country is not impacting the trial sites located there in terms of recruitment and ongoing support of patients."
Click to read the ASX release.
